Drug intelligence / Profile preview

GR-1405

Development stage: Phase 1
Lead developer: Zhixiang (Shanghai) Medical Technology
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

GR-1405 is a PD-L1 inhibitor antibody drug that was developed for the treatment of advanced solid tumors. It was administered intravenously in clinical trials to evaluate its tolerability, safety, pharmacokinetics, and preliminary efficacy. The drug was initially developed by Zhixiang (Shanghai) Medical Technology Co., Ltd., but its development has been discontinued.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on GR-1405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GR-1405.

Explore the full profile